Simulations Plus SLP

Simulations Plus, Inc. is a company that provides modeling and simulation software and related services to the pharmaceutical and biotechnology industries to support drug development. The company's solutions enable clients to accelerate the discovery and development of new therapeutics, reduce research and development costs, comply with regulatory requirements, and improve confidence in drug safety and efficacy. Simulations Plus operates through a remote work culture with headquarters in Research Triangle Park, North Carolina, and a European office in Paris, France.

Simulations Plus generates revenue primarily from the sale of software licenses and the provision of consulting and implementation services. Software revenue comes from the sale of perpetual and term licenses for its modeling and simulation platforms used across the drug development lifecycle. Service revenue is derived from professional services including consulting, training, customization, and support for clients utilizing the company's software solutions. The company serves pharmaceutical and biotechnology companies engaged in drug discovery, development, and commercialization activities.

The company operates through the following segments: Software and Services.

• The Software segment includes the development, licensing, and maintenance of proprietary modeling and simulation software products used in drug discovery, development, and clinical trial planning. These products support activities such as pharmacokinetics, pharmacodynamics, formulation development, and drug-drug interaction analysis. Revenue in this segment is generated from software licenses, updates, and technical support.
• The Services segment provides professional services including consulting, implementation, training, and customization of the company's software solutions for clients. These services help pharmaceutical companies apply modeling and simulation techniques to their specific drug development projects, ensuring proper use of the software and integration into their research workflows. Revenue in this segment is derived from time-and-materials engagements and fixed-fee projects.

Simulations Plus holds a specialized position in the pharmaceutical technology industry as a provider of model-informed drug development (MIDD) software and services. The company competes with other firms offering simulation and modeling tools for drug development, though it differentiates itself through its long-standing focus on pharmaceutical applications, validated scientific engines, and integrated workflow capabilities across the drug development lifecycle. Competitive advantages include proprietary scientific algorithms, regulatory expertise, and a track record of supporting regulatory submissions and approvals.

The company serves pharmaceutical and biotechnology companies engaged in drug research and development. Its customer base includes organizations involved in small molecule and biologic drug discovery, preclinical development, clinical trial design, and regulatory submission processes. Specific customer names are not disclosed in the filing.